The interleukin-13 receptor alpha 2 (IL13RA2) and ephrin type A receptor 2 (EPHA2) are attractive therapeutic targets, being expressed in ~90% of canine and human gliomas, and absent in normal brain. Clinical trials using an earlier generation IL-13 based cytotoxin showed encouraging clinical effects in human glioma, but met with technical barriers associated with the convection-enhanced delivery (CED) method. In this study, IL-13 mutant and ephrin A1 (EFNA1)–based bacterial cytotoxins targeted to IL13RA2 and EPHA2 receptors, respectively, were administered locoregionally by CED to dogs with intracranial gliomas to evaluate their safety and preliminary efficacy.

中文翻译：

---

对流增强IL13RA2和EPHA2受体靶向细胞毒素在自发性颅内神经胶质瘤犬中的I期试验

白介素13受体α2（IL13RA2）和ephrin A型受体2（EPHA2）是有吸引力的治疗靶标，在约90％的犬和人神经胶质瘤中表达，在正常脑中不存在。使用较早一代基于IL-13的细胞毒素进行的临床试验显示出对人脑胶质瘤的令人鼓舞的临床效果，但遇到了与对流增强递送（CED）方法相关的技术障碍。在这项研究中，分别通过CED对患有颅内神经胶质瘤的狗局部定位了针对IL13RA2和EPHA2受体的IL-13突变体和基于ephrin A1（EFNA1）的细菌细胞毒素，以评估其安全性和初步疗效。